CureVac NV (NASDAQ:CVAC)

111.20
Delayed Data
As of Apr 20
 -2.22 / -1.96%
Today’s Change
36.15
Today|||52-Week Range
151.80
+37.17%
Year-to-Date
2 Reasons This COVID Vaccine Latecomer Could Gain Major Market Share
6:30am / MotleyFool.com - Paid Partner Content
CureVac (CVAC) Q4 2020 Earnings Call Transcript
Apr 15 / MotleyFool.com - Paid Partner Content
Novartis (NVS) Collaborates with Roche for API of RA Drug Actemra
Apr 16 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close113.00
Today’s open109.94
Day’s range106.58 - 111.27
Volume1,038,693
Average volume (3 months)850,112
Market cap$21.0B
Data as of 4:00pm ET, 04/20/2021

Growth & Valuation

Earnings growth (last year)-33.01%
Earnings growth (this year)--
Earnings growth (next 5 years)-113.50%
Revenue growth (last year)+28.37%
P/E ratioNM
Price/Sales--
Price/Book--

Competitors

No competitors data available.

Financials

Last reporting date--
EPS forecast (this quarter)-$0.52
Annual revenue (last year)$19.5M
Annual profit (last year)-$111.8M
Net profit margin-573.46%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Major
No executives to display
Corporate headquarters
--, --

Forecasts